Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effects of Daratumumab Monotherapy on Bone Parameters in Patients With Relapsed and /or Refractory Multiple Myeloma (REBUILD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03475628
Recruitment Status : Recruiting
First Posted : March 23, 2018
Last Update Posted : March 23, 2018
Sponsor:
Collaborator:
Janssen Pharmaceuticals
Information provided by (Responsible Party):
Hellenic Society of Hematology

Brief Summary:
The purpose of this study is to evaluate the effects of daratumumab monotherapy on bone disease in patients with relapsed/refractory MM who have received at least 2 prior lines of therapy, including lenalidomide and a PI.

Condition or disease Intervention/treatment Phase
Multiple Myeloma Drug: Daratumumab Phase 2

Detailed Description:

This is a prospective, multicenter, non-comparative, open-label Phase II study. Daratumumab will be administered according to approved label. Approximately 57 subjects located in Greece will be enrolled in the study.

Patients shall receive treatment until disease progression, physician decision, unacceptable toxicity, withdrawal of consent, or death (whichever occurs first). Survival status and data of subsequent anti-myeloma treatment will be collected post-treatment.

Primary and secondary variables related to bone disease markers will be evaluated every other cycle of therapy. Disease evaluations will occur monthly and consist mainly of measurements of myeloma proteins. Other parameters may include bone marrow examinations, skeletal surveys, assessment of extramedullary plasmacytomas, and measurements of serum calcium corrected for albumin, and β2- microglobulin and albumin. Assessment of myeloma response and disease progression will be conducted in accordance with the modified IMWG response criteria


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 57 participants
Intervention Model: Single Group Assignment
Intervention Model Description: Single arm: Daratumumab
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective, Multicenter, Non-comparative, Open-label, Phase II Study to Evaluate the Effects of Daratumumab Monotherapy on Bone Parameters in Patients With Relapsed and /or Refractory Multiple Myeloma Who Have Received at Least 2 Prior Lines of Therapy, Including Lenalidomide and a Proteasome Inhibitor
Actual Study Start Date : February 21, 2018
Estimated Primary Completion Date : June 20, 2019
Estimated Study Completion Date : February 20, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Multiple Myeloma
Drug Information available for: Daratumumab

Arm Intervention/treatment
Experimental: Daratumumab
Daratumumab at a dose of 16 mg/kg administered as an IV infusion at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter.
Drug: Daratumumab
Daratumumab will be given at a dose of 16 mg/kg administered as an IV infusion at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter. Subjects will receive pre-infusion medications prior to Daratumumab infusion to mitigate potential IRRs and post- infusion medications after Daratumumab infusion for the prevention of delayed IRRs




Primary Outcome Measures :
  1. changes in bone resorption marker, C-telopeptide of collagen type 1 (CTX), after 4 months of daratumumab monotherapy [ Time Frame: assessed on baseline and after 4 months from initiation of daratumumab monotherapy ]
    The evaluation of the changes in bone resorption marker after 4 months of daratumumab monotherapy. CTX (measured in pg/ml) will be evaluated at baseline and then every 2 months of therapy.

  2. changes in bone resorption marker, namely, tartrate-resistant acid phosphatase-5b (TRACP-5b) after 4 months of daratumumab monotherapy [ Time Frame: assessed on baseline and after 4 months from initiation of daratumumab monotherapy ]
    The evaluation of the changes in bone resorption marker after 4 months of daratumumab monotherapy. TRACP-5b (measured in mU/dL) will be evaluated at baseline and then every 2 months of therapy


Secondary Outcome Measures :
  1. Changes in bone formation marker, bALP. [ Time Frame: from baseline up to 12 months of daratumumab monotherapy or at end of treatment ]
    Change from baseline in bone formation marker bALP (measured in U/L) after 4, 8 and 12 months of daratumumab monotherapy (or at the end of therapy)

  2. Changes in bone formation marker, OC. [ Time Frame: from baseline up to 12 months of daratumumab monotherapy or at end of treatment ]
    Change from baseline in bone formation marker OC (measured in ng/ml) after 4, 8 and 12 months of daratumumab monotherapy (or at the end of therapy)

  3. Changes in bone formation marker, PINP. [ Time Frame: from baseline up to 12 months of daratumumab monotherapy or at end of treatment ]
    Change from baseline in bone formation marker PINP (measured in ng/ml) after 4, 8 and 12 months of daratumumab monotherapy (or at the end of therapy)

  4. Changes in bone resorption marker, CTX. [ Time Frame: from baseline up to12 months of daratumumab monotherapy or at end of treatment ]
    Change from baseline in bone resorption marker CTX (measured in pg/ml) after 8 and 12 months of daratumumab monotherapy

  5. Changes in bone resorption marker, TRACP-5b. [ Time Frame: from baseline up to12 months of daratumumab monotherapy or at end of treatment ]
    Change from baseline in bone resorption marker TRACP-5b (measured in mU/dL) after 8 and 12 months of daratumumab monotherapy

  6. Changes in bone marker RANKL [ Time Frame: from baseline up to 12 months of daratumumab monotherapy or at end of treatment ]
    Change from baseline in RANKL (measured in pg/ml) after 4, 8 and 12 months of daratumumab monotherapy

  7. Changes in bone marker ratio,RANKL/OPG ratio. [ Time Frame: from baseline up to 12 months of daratumumab monotherapy or at end of treatment ]
    Change from baseline in RANKL/OPG ratio after 4, 8 and 12 months of daratumumab monotherapy

  8. Changes in bone marker CCL3 [ Time Frame: from baseline up to 12 months of daratumumab monotherapy or at end of treatment ]
    Change from baseline in CCL3 (measured in pg/ml) after 4, 8 and 12 months of daratumumab monotherapy

  9. Changes in bone marker Dkk1 [ Time Frame: from baseline up to 12 months of daratumumab monotherapy or at end of treatment ]
    Change from baseline in Dkk1 (measured in ng/ml) after 4, 8 and 12 months of daratumumab monotherapy

  10. Changes in bone marker SOST [ Time Frame: from baseline up to 12 months of daratumumab monotherapy or at end of treatment ]
    Change from baseline in SOST (measured in pmol/L) after 4, 8 and 12 months of daratumumab monotherapy

  11. Changes in bone marker activin-A [ Time Frame: from baseline up to 12 months of daratumumab monotherapy or at end of treatment ]
    Change from baseline in activin-A (measured in μg/L) after 4, 8 and 12 months of daratumumab monotherapy

  12. Change in Bone Mineral Density (BMD) of lumbar spine [ Time Frame: measured at baseline and after 6 and 12 months after initiation of daratumumab monotherapy ]
    Change in Bone Mineral Density (BMD) of lumbar spine measured by DXA after 6 and 12 months of daratumumab monotherapy

  13. Immunomodulatory effects of daratumumab on T cells by comprehensive molecular and phenotypic studies and correlations with bone markers [ Time Frame: : measured at baseline and after 3 and 6 months after initiation of daratumumab monotherapy ]
    Immunomodulatory effects of daratumumab on T cells by comprehensive molecular and phenotypic studies and correlations with bone markers

  14. Progression free survival (PFS) [ Time Frame: from recruitment to the date of the first documented PD or death due to any cause, whichever comes first (approximately up to 2 years). ]
    Progression free survival is defined as the time, in months, from recruitment to the date of the first documented PD or death due to any cause, whichever comes first. PD will be assessed by the investigator based on the analysis of serum and urine protein electrophoresis (sPEP and uPEP), serum free light chain protein (sFLC), Corrected serum calcium assessment, imaging and bone marrow assessments as per modified IMWG guidelines.

  15. Overall survival [ Time Frame: Time from first dose of study treatment to death (approximately up to 2 years) ]
    Overall survival is defined as the time, in months

  16. Time to next treatment [ Time Frame: From first dose until the date to next anti-neoplastic therapy or death from any cause, whichever comes first (approximately up to 2 years) ]
    Time to next therapy will be defined as the time, in months.

  17. Spinal cord compression (Skeletal surveys-Skeletal related events) [ Time Frame: From baseline to 24 months (up to 2 years) ]
    Spinal cord compression will be evaluated in terms of number (and percentage) of patients with events and number of events per patient

  18. The incidence of pathological fractures (Skeletal surveys-Skeletal related events) [ Time Frame: From baseline to 24 months (up to 2 years) ]
    The incidence of pathological fractures will be evaluated in terms of number (and percentage) of patients with events and number of events per patient

  19. Need for radiotherapy or surgery to the bones (Skeletal surveys-Skeletal related events) [ Time Frame: From baseline to 24 months (up to 2 years) ]
    Need for radiotherapy or surgery to the bones will be evaluated in terms of number (and percentage) of patients with events and number of events per patient

  20. Safety (adverse events) [ Time Frame: Continuously throughout the study, starting from informed consent until 30 days after last study treatment (approximately up to 30 months) ]
    The incidence of Adverse Events will be assessed according to the common Terminology Criteria for Adverse Events.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Males and females at least 18 years of age.
  2. Voluntary written informed consent.
  3. Subject must have documented relapsed or refractory multiple myeloma as defined by the criteria below:

    a. Measurable disease as defined by any of the following:

    • Serum monoclonal paraprotein (M-protein) level ≥ 1.0 g/dL (except for IgA subtype: ≥ 0.5 g/dL) or urine M-protein level ≥ 200 mg/24 hours; or
    • Light chain multiple myeloma for subjects without measurable disease in the serum or urine by SPEP/UPEP: Serum immunoglobulin free light chain ≥ 10 mg/dL and abnormal serum immunoglobulin kappa lambda free-light-chain ratio.
  4. Prior treatment with at least two lines of therapy including lenalidomide and a PI for MM (induction followed by any planned high dose therapy or consolidation or maintenance would be considered as one regimen).
  5. Documented evidence of progressive disease as defined by the IMWG 2014 on or after the last regimen.
  6. Karnofsky Performance Status score of ≥ 70.
  7. All of the following laboratory test results during screening:

    • Absolute neutrophil count (ANC) of ≥1.0 x 109/L.
    • Platelet count of ≥ 75 x 109/L in patients in whom <50% of bone marrow nucleated cells are plasma cells and ≥50 x 109/L in patients in whom more than 50% of bone marrow nucleated cells are plasma cells.
    • Hemoglobin value (> 7.5 g/dL).
    • Alanine aminotransferase level ≤2.5 times the upper limit of normal (ULN).
  8. Adequate renal function (CrCl ≥ 30 mL/min by CKD-EPI).
  9. Willingness and ability to participate in study procedures.
  10. Reproductive Status:

    1. Women of childbearing potential (WOCBP) must have two negative serum or urine pregnancy tests, one 10-14 days prior to start of the study drug and one within 24 hours prior to the start of study drug.
    2. Women must not be breastfeeding.
    3. WOCBP must agree to follow instructions for effective methods of contraception for 4 weeks before the start of treatment with study drugs, for the duration of treatment with study drugs, and for 3 months after cessation of study treatment.

Male patients must use a latex or synthetic condom during any sexual contact with females of reproductive potential, even if they have undergone a successful vasectomy. They must also agree to follow instructions for methods of contraception for 4 weeks before the start of treatment with study drugs, for the duration of treatment with study drugs, and for a total of 3 months post-treatment completion.

Exclusion Criteria:

  1. Patient has received any of the following therapies:

    • Radiotherapy or systemic therapy within 2 weeks of baseline.
    • Prior Allogeneic hematopoietic stem cell transplantation within 12 weeks of baseline.
    • Prior Treatment with any CD38-antibody (i.e. isatuximab).
  2. Clinically significant cardiac disease, including:

    1. Myocardial infarction within 6 months, or unstable or uncontrolled condition (e.g., unstable angina, congestive heart failure, New York Heart Association Class III-IV).
    2. Cardiac arrhythmia (CTCAE Grade 3 or higher) or clinically significant ECG abnormalities.
    3. ECG showing a baseline QT interval as corrected >470 msec.
  3. Chronic obstructive pulmonary disease (COPD) with a Forced Expiratory Volume in 1 second (FEV1) <50% of predicted normal. Note that FEV1 testing is required for subjects suspected of having COPD and subjects must be excluded if FEV1 <50% of predicted normal.
  4. Known active hepatitis A, B, or C.
  5. Known HIV infection.
  6. Significant neuropathy (Grades 3-4, or Grade 2 with pain) within 14 days prior to enrolment.
  7. Hypersensitivity to the active substance or to any of the excipients.
  8. Any concurrent medical or psychiatric condition or disease (e.g., active systemic infection, uncontrolled diabetes, acute diffuse infiltrative pulmonary disease) that is likely to interfere with subject's ability to give informed consent, the study procedures or results, or that in the opinion of the investigator, would constitute a hazard for participating in this study.
  9. Pregnant or breastfeeding women.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03475628


Contacts
Layout table for location contacts
Contact: Panayiotidis Panayiotis, Prof. +30 2107211806 infohaema@eae.gr

Locations
Layout table for location information
Greece
General Hospital of Athens "Alexandra" Recruiting
Athens, Attica, Greece, 11528
Contact: Evangelos Terpos, Assoc Prof    +30210 3381512      
Sponsors and Collaborators
Hellenic Society of Hematology
Janssen Pharmaceuticals
Investigators
Layout table for investigator information
Principal Investigator: Evangelos Terpos, Assoc Prof Department of Clinical therapeutics, National and Kapodistrian University of Athens, School of medicine, Athens, Greece

Layout table for additonal information
Responsible Party: Hellenic Society of Hematology
ClinicalTrials.gov Identifier: NCT03475628     History of Changes
Other Study ID Numbers: EAE-2017/MM01
First Posted: March 23, 2018    Key Record Dates
Last Update Posted: March 23, 2018
Last Verified: March 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Daratumumab
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Antibodies, Monoclonal
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs